Get the Stockscreener App
26.57
2.53%
0.685
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $26.57, with a volume of 55.74M.
It is up +2.53% in the last 24 hours and up +5.76% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.88
Open:
$25.94
24h Volume:
55.74M
Relative Volume:
0.89
Market Cap:
$150.98B
Revenue:
$62.79B
Net Income/Loss:
$9.84B
P/E Ratio:
15.48
EPS:
1.7156
Net Cash Flow:
$10.38B
1W Performance:
+3.98%
1M Performance:
+5.76%
6M Performance:
+7.04%
1Y Performance:
-1.21%
1-Day Range:
$25.90
$26.83
1-Week Range:
$25.38
$26.83
52-Week Range:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.55 | 147.15B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,051.19 | 951.18B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
225.08 | 533.63B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.55 | 390.19B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
151.84 | 286.13B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.91 | 284.29B | 46.69B | 15.29B | 9.25B | 3.4329 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline - Finviz
CMA Seeks To Appeal Re-Do Of £70M Pfizer, Flynn Drug Fines - Law360
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
118,500 Shares in Pfizer Inc. $PFE Acquired by Y Intercept Hong Kong Ltd - MarketBeat
These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively - Yahoo Finance
Macrolide Antibiotics Market to Witness Stunning Growth - openPR.com
Pfizer vs. Merck Stock And JNJ - Forbes
With 66% Ownership of the Shares, Pfizer Inc. (NYSE:PFE) Is Heavily Dominated by Institutional Owners - 富途牛牛
Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance (NYSE:PFE) - Seeking Alpha
What Are Wall Street Analysts' Target Price for Pfizer Stock? - Barchart.com
Pfizer (PFE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Pfizer Recasts Infectious Disease Focus With ViiV Exit And Matrix M Access - simplywall.st
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
Recent Report Shows That Rep. French Hill Sold Up to $365K Worth of Pfizer Stock - Benzinga
Pfizer Stock Forecast 2026–2030 | Future Outlook - Capital.com
Parthenon LLC Has $1.27 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Callahan Advisors LLC Acquires 43,454 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Avantax Planning Partners Inc. - MarketBeat
Pfizer to exit ViiV Healthcare as GSK and Shionogi reshape ownership - MSN
Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance
Quilter Plc Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Sector Gamma AS Increases Stake in Pfizer Inc. $PFE - MarketBeat
UniSuper Management Pty Ltd Increases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Commerzbank Aktiengesellschaft FI Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Refines Vaccine Toolkit With Matrix M Deal And ViiV Exit - simplywall.st
The Best Stocks to Invest $40 in to Start the New Year Off Right - Finviz
Pfizer Inc. $PFE Stock Position Lessened by Resona Asset Management Co. Ltd. - MarketBeat
Rakuten Investment Management Inc. Buys New Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Refocuses Portfolio With Matrix M Deal And ViiV Exit - simplywall.st
Lobbying Update: $2,810,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (NYSE:PFE) Stock Price Down 1.7%Here's What Happened - MarketBeat
Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld MedTech
Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research - Benzinga
Pfizer’s New Autoimmune Candidate PF-08065010 Enters Phase 1: What Investors Should Watch - TipRanks
Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know - TipRanks
Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline - TipRanks
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview) (NYSE:PFE) - Seeking Alpha
The Top Stock to Buy With $30 for 2026 - Finviz
Pfizer Inc. $PFE Shares Purchased by Teacher Retirement System of Texas - MarketBeat
Lockheed Martin Investment Management Co. Grows Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Position Raised by Strs Ohio - MarketBeat
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Pfizer (PFE) Valuation Check As Shares Recover Modestly From Longer Term Weakness - simplywall.st
Pfizer Target of Unusually High Options Trading (NYSE:PFE) - MarketBeat
Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress - TipRanks
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies - BioSpace
How Is The Market Feeling About Pfizer Inc? - Benzinga
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):